

It is made available under a [CC-BY-NC-ND 4.0 International license](#) .
Association between having a pregnancy complicated by vaginal bleeding and risk of cancer

1 **Title: Association between having a pregnancy complicated by vaginal bleeding and risk of**
2 **cancer**

3 Elena Dudukina,¹ Erzsébet Horváth-Puhó,¹ Henrik Toft Sørensen,¹ Vera Ehrenstein¹

4 ¹Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus,
5 Denmark

6 **Corresponding author:**

7 Elena Dudukina

8 Olof Palmes Alle 43-45

9 8200, Aarhus N, Denmark

10 Email: e.dudukina@clin.au.dk

11 ORCID identifier: 0000-0002-4238-049X

1 **ABSTRACT (MAX 200/200)**

2 **Background:** A full-term pregnancy is associated with a lower cancer risk. The risk of cancer in
3 women with vaginal bleeding in pregnancy is unknown.

4 **Methods:** We conducted a registry-based cohort study (1995-2017) in Denmark. We included
5 pregnancies (n=37 082) affected by vaginal bleeding (VB) within 20 gestational weeks among
6 35 514 women, VB-unaffected pregnancies (n=1 363 614) among 783 314 women, pregnancies
7 ending in a termination (n=324 328) among 239 638 women or miscarriage (n=137 104) among
8 121 353 women. We computed absolute risk of cancer and hazard ratios (HR) with 95%
9 confidence intervals (CI) adjusted for age, calendar year, morbidity, and socioeconomic factors
10 using Cox proportional hazards regression.

11 **Results:** At the end of the 24-year follow-up, there were 1 320 events among VB-affected cohort,
12 40 420 events among VB-unaffected cohort, 10 300 events among termination cohort, and 4 790
13 events among miscarriage cohort. The HR for any cancer was 1.03 (95% CI: 0.97-1.08) when
14 comparing VB-affected vs VB-unaffected pregnancies, 1.03 (95% CI: 0.97-1.09) vs terminations,
15 and 0.90 (95% CI: 0.84-0.95) vs miscarriages. Similar results were obtained for site-specific
16 cancers.

17 **Conclusions:** We found no strong evidence for an association between vaginal bleeding in
18 pregnancy and an increased risk of cancer.

19 Abstract word count: 200

20 Word count: 2992

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .
Association between having a pregnancy complicated by vaginal bleeding and risk of cancer

1 INTRODUCTION

2 Gestation is sustained with progesterone, which may play a protective role for hormone-related
3 cancers, such as endometrial and breast cancer (1,2). Threatened miscarriage and completed
4 miscarriage share several biologic mechanisms, including increased levels of pro-inflammatory
5 cytokines (3–5) and decreased levels of progesterone (6,7). Threatened miscarriage affects up to 30%
6 (8–12) of clinically identified pregnancies and manifests as vaginal bleeding (VB) before 20
7 gestational weeks of a viable intrauterine pregnancy (8,9,13). About 30-50% (6,14,15) of VB-affected
8 pregnancies may progress to a completed miscarriage (16–18). Previously reported risk factors for VB
9 in pregnancy are advanced women’s age at pregnancy (≥ 35 years), obesity, smoking, alcohol abuse,
10 inflammation, and low plasma levels of progesterone in gestation (16,19–26).
11 A full-term pregnancy is associated with a 40% reduction in risks of breast, endometrial, and ovarian
12 cancer (27,28). Pregnancies with a duration of 33 gestational week or more were not associated with
13 increased risk of breast cancer in contrast to pregnancies with shorter gestation (1,2,27). In line with
14 this, a full-term pregnancy is associated with a 40% cancer risk reduction (27,28); however, reduction
15 in cancer risk after a pregnancy ending in a miscarriage is only 10% (1). The long-term risk of cancer
16 in women with a pregnancy complicated by VB within 20 gestational weeks is unknown and could be
17 increased due to underlying inflammatory pathways and reduced level of progesterone. In this cohort
18 study, we investigated an association between having a VB-affected pregnancy ending in childbirth
19 with the subsequent risk of cancer as compared with VB-unaffected pregnancy ending in childbirth,
20 pregnancy ending in a termination or pregnancy ending in miscarriage.

21

22 METHODS

23 Setting, design and data sources

24 This was a registry-based cohort study conducted using individual-level linked data from Danish
25 health and administrative registries, set within Denmark’s universal and tax-funded health care system
26 (29). The Civil Registration System assigns personal identifiers and contains data on date of birth,
27 vital and civil status, and dates of immigration and emigration (29,30). Data on all deliveries are
28 captured by the Medical Birth Registry (MBR) starting in 1973 and includes women’s and pregnancy-
29 related characteristics including but not limited to women’s age at delivery, gestational age, and parity
30 (31,32). Smoking status in pregnancy is collected by the MBR from 1991 and body-mass index (BMI)
31 from 2004. Information on stillbirths at the gestational age of at least 28 full weeks is available in the
32 MBR before April 2004 and at 22 full gestational weeks afterwards; livebirths are recorded regardless
33 of gestational age. Information on highest education level (33), employment status (34) and personal
34 income (35) are stored at Statistics Denmark and available starting in 1980-1981 (36). Hospital
35 encounters are recorded in the Danish National Patient Registry (DNPR) (37,38), including data on

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .
Association between having a pregnancy complicated by vaginal bleeding and risk of cancer

1 medical procedures and discharge diagnoses, coded using the International Classification of Diseases,
2 8th revision (ICD-8) in 1977-1993 and 10th revision (ICD-10) thereafter (37). Hospital admissions are
3 available in the DNPR from 1977, while outpatient clinic and emergency room visits are recorded
4 from 1995 onwards (37,38). Admissions and outpatient specialist visits due to psychiatric conditions
5 are captured as part of the the DNPR (39) and were available for this study from 1995. The Danish
6 National Prescription Registry (40) captures data on prescribed medication dispensings from 1995
7 onwards and records the Anatomical Therapeutic Classification (ATC) codes of the dispensed drugs
8 and the dates when the prescriptions were redeemed. The Danish Cancer Registry (DCR) captures all
9 primary incident cancer diagnoses (with compulsory reporting from 1987) and contains data on
10 tumour morphology (41).

11 **Study population**

12 Using the MBR, we identified all pregnancies ending in a liveborn or stillborn delivery between 1995
13 and 2017. We kept one record per delivery of a multifetal pregnancy. Using the DNPR, we obtained
14 and linked data on VB within 20 gestational weeks starting from the last menstrual period date,
15 computed by subtracting gestational age at delivery from the delivery date (Table 1 in the electronic
16 supplementary material). Pregnancies ending in a delivery without a VB record in the DNPR within
17 20 weeks of gestation were classified as VB-unaffected. The date of delivery served as the start of the
18 follow-up for both VB-affected and VB-unaffected cohorts of pregnancies.

19 Using the DNPR, we identified pregnancies ending in a miscarriage (spontaneous abortion) or a
20 termination (medical or surgical abortion) in 1995-2017, using relevant diagnostic and procedure
21 codes (Table 1 in the electronic supplementary material). To avoid multiple counting of the same
22 miscarriages or terminations, a woman with repeated event-qualifying diagnostic or procedure code
23 was allowed to re-enter the cohort after 180 days, whereby she was assumed to have a new pregnancy.
24 When multiple dates associated with the pregnancy termination or miscarriage were available (date of
25 procedure, date of hospital admission, date of hospital discharge), we included the earliest. The date
26 of the hospital-based encounter for pregnancy termination or miscarriage served as the index date. We
27 excluded from the study pregnancy records of women with cancer or HIV/AIDS diagnosis before the
28 index date, records with missing women's age at the pregnancy end, and pregnancies ending in
29 childbirth with missing gestational age. The flow-chart for study population construction is presented
30 in Figure 1.

31 **Cancer outcomes**

32 Using the DCR, we ascertained incident diagnoses of cancer. We investigated the long-term risk of
33 any cancer; cancers at specific anatomic sites, focusing on breast, cervical, ovarian and fallopian tube,
34 and uterine cancer, and cancers grouped as hormone-related, haematological, immune-related,

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .
Association between having a pregnancy complicated by vaginal bleeding and risk of cancer

1 smoking or alcohol-related, obesity-related, and cancers of neurological origin, as previously
2 described (42–44)(Table 1 in the electronic supplementary material).

3 **Covariables**

4 The potential confounding factors were age, calendar year of pregnancy end, women’s parity, number
5 of previous identifiable pregnancies, socioeconomic factors (education, employment, and year-
6 specific income level divided into quartiles), reproductive factors (pre-index date vaginal bleeding,
7 termination, or miscarriages, placental complications in previous and current deliveries), chronic
8 somatic conditions (obesity, polycystic ovary syndrome, thyroid disorders, chronic kidney disease,
9 chronic liver disease, hyperlipidaemia, diabetes, hypertension, and connective tissue disorder), and
10 history of any psychiatric condition using the entire available lookback period. We additionally
11 adjusted for the use of NSAIDs and steroids for systemic use before the 12 weeks of gestation for VB-
12 affected and VB-unaffected pregnancies and before the index date for terminations and miscarriages
13 using 365 days lookback period for NSAIDs and the entire available lookback period for steroids for
14 systemic use. In the comparisons of pregnancies ending in childbirth, we additionally controlled for
15 placental complications (hypertensive disorders of pregnancy, placenta praevia, and abruptio
16 placenta) not only at the previous deliveries but also at the index pregnancy as a late manifesting
17 proxy of potential placental dysfunction early in pregnancy.

18 **Statistical analyses**

19 We followed each woman from the index date until the earliest of cancer diagnosis, death, emigration,
20 or end of the study on 31 December 2018. We constructed the cumulative incidence curves of any
21 cancer at the end of a 24-year follow-up while treating death and emigration as competing events
22 (Figure 1 in the electronic supplementary material) and calculated cancer incidence rates (IRs) per
23 10 000 person-years (PYs). We used Cox proportional-hazards regression to compute crude and
24 adjusted hazard ratios (HRs) for the cancer outcomes. In the analyses of all pregnancies, with each
25 subsequent pregnancy of a woman, we accounted for the reproductive history, including prior
26 exposure status, at the previous pregnancies. We computed robust 95% confidence intervals (CIs)
27 taking into account that different non-independent pregnancies of the same woman were analysed
28 (45). Further, we repeated the main analyses following women’s first identifiable pregnancy. In
29 separate sets of analyses, we compared the risk of cancer outcomes following a VB-affected
30 pregnancy vs 1) VB-unaffected pregnancy, 2) termination, or 3) miscarriage.

31 The HRs were adjusted for potential confounders (women’s age at pregnancy end, calendar period,
32 socioeconomic factors [education, employment, and year-specific income level divided into quartiles],
33 reproductive history [parity, number of pre-index date identifiable pregnancies, history of VB,
34 terminations or miscarriages, hypertensive disorders of pregnancy, placenta praevia, abruptio
35 placentae] and placenta-related complications at the current pregnancy ending in delivery

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .
Association between having a pregnancy complicated by vaginal bleeding and risk of cancer

1 [preeclampsia-eclampsia, placenta praevia, abruptio placentae]; pre-index date thyroid conditions,
2 obesity, polycystic ovary syndrome, chronic obstructive pulmonary disease, chronic liver and kidney
3 diseases, connective tissue disorders and medication use [non-steroid anti-inflammatory drugs and
4 steroid for systemic use]). In analyses of all identifiable pregnancies of a woman, we ascertained the
5 history of all covariables before the index date in a time-varying manner updating the covariables'
6 status at each subsequent pregnancy.

7 In a sensitivity analysis, we investigated the association of VB-affected pregnancy with any cancer
8 and hormone-related, haematological, immune-related, smoking or alcohol-related, obesity-related,
9 and cancers of neurological origin additionally adjusted for women's BMI in analyses of pregnancies
10 ending in a delivery; however, the follow-up was short and accrued few events. We additionally
11 investigated the associations with cancer outcomes restricting the data to women having their last
12 recorded pregnancy at the age of 40 years or later as the age, when most women likely reach the
13 desired family size. We did not impute missing values and included variables with missing data in the
14 statistical models using "missing" as a category.

15 We used log-minus-log plots to evaluate the proportionality of hazards assumptions, and the curves
16 were close to parallel over the follow-up period for overall cancer. All analyses were conducted on the
17 servers of Statistics Denmark (36) using RStudio (46) and R software for statistical computing (47)
18 versions 3.6.0-4.1.0, including the following packages and their dependencies: tidyverse (48), ggplot2
19 (49), survival (45), cmprsk (50), prodlim (51), and epiR (52). Reported counts were masked to protect
20 personal data, in compliance with the Statistics Denmark regulations.

21 **Ethics**

22 Patient consent or ethical approval is not required for registry-based research according to Danish
23 legislation. This study was reported to the Danish Data Protection Agency (53) through registration at
24 Aarhus University (record number: AU-2016-051-000001, sequential number 605).

25 **RESULTS**

26 **Descriptive characteristics**

27 There were 37 082 VB-affected pregnancies among 35 514 women; 1 363 614 VB-unaffected
28 pregnancies among 783 314 women; 324 328 terminations among 239 638 women and 137 104
29 miscarriages among 121 353 women in 1995-2017 (Figure 1). Women's age, parity, civil status,
30 employment, income, obesity, chronic pulmonary, chronic liver and kidney conditions, alcohol abuse,
31 and medication use had similar distributions for VB-affected and VB-unaffected pregnancy cohorts.
32 Of women with VB-affected vs VB-unaffected pregnancies, 29.0% vs 35.0% had higher education,
33 13.0% vs 4.9% had a previous record of VB diagnosis irrespective of pregnancy outcome, 6.2% vs
34 2.1% had a history of a previous VB episode within 20 gestational weeks of a pregnancy ending in a

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .
Association between having a pregnancy complicated by vaginal bleeding and risk of cancer

1 delivery, 22.0% vs 12.0% had at least one previous miscarriage; 19.0% vs 15.0% were smokers
2 (Table 1).

3 Pregnancies ending in a termination were more likely to be among women who were younger (<24
4 years), unmarried, nulliparous and unemployed, had a higher prevalence of psychiatric conditions
5 history, a lower level of the highest attained education and were in the first income quartile compared
6 with pregnancies ending in a delivery or miscarriage (Table 1). Pregnancies ending in a miscarriage
7 were more likely than VB-affected pregnancies to be of women older than 35 years and 15.0% had a
8 previous miscarriage (Table 1).

9 **Cumulative incidences and incidence rates of the cancer outcomes**

10 The median (25th-75th percentile) follow-up was 12.6 (6.9-18.2) years. At the end of the follow-up,
11 there were 1 320 cancer events following VB-affected pregnancy, 40 420 events following VB-
12 unaffected pregnancy, 10 300 events following a termination and 4 790 events following a
13 miscarriage (Table 2). At the end of the 24-year follow-up, the cumulative incidence of any cancer
14 was 7.4% following VB-affected pregnancy and 7.5% following VB-unaffected pregnancy, 7.3%
15 following termination and 7.9% following a miscarriage (Figure 1 in the electronic supplementary
16 material). The cumulative incidence of groups of site-specific cancers was also similar between the
17 investigated cohorts. Cancers classified as hormone-related were the most prevalent group with
18 cumulative incidences at the end of follow-up of 3.2%, 3.0%, 2.6%, and 3.0% following VB-affected
19 pregnancy, VB-unaffected pregnancy, termination, and miscarriage, respectively.

20 The incidence rate per 10 000 PYs of any cancer was 25.36 (95% CI: 24.02-26.76) for VB-affected
21 pregnancies and 24.04 (95% CI: 23.81-24.28) for VB-unaffected pregnancies (Table 2). The incidence
22 rates per 10 000 PYs of hormone-related cancers were 9.83 (9.01-10.71) for VB-unaffected
23 pregnancies, 9.19 (9.05-9.34) for VB-affected pregnancies, 8.20 (7.94-8.48) for terminations, and
24 10.56 (10.09-11.05) for miscarriages. Similarly, the incidence rates per 10 000 PYs of smoking or
25 alcohol-related cancers and obesity-related cancers were slightly higher following VB-affected than
26 VB-unaffected pregnancy. The incidence rates of premenopausal breast cancer, cervical cancer, ovary
27 and fallopian tube cancer, uterine cancer, and cancers at other sites were similar for all investigated
28 cohorts (Table 2 and Table 2 in the electronic supplementary material).

29 **Hazard ratios for the cancer outcomes**

30 The HR for any cancer in the VB-affected pregnancy cohort was 1.03 (95% CI: 0.97-1.08) vs VB-
31 unaffected pregnancy cohort, 1.03 (95% CI: 0.97-1.09) vs termination cohort, and 0.90 (95% CI:
32 0.84-0.95) vs miscarriage cohort. In the analyses including the first pregnancy of a woman, the
33 adjusted models yielded nearly identical results as analyses including all identifiable pregnancies of a
34 woman (Table 3).

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .
Association between having a pregnancy complicated by vaginal bleeding and risk of cancer

1 There was no strong evidence for an association between VB-affected pregnancy and subsequent risk
2 of hormone-related, haematological, immune-related, obesity-related, cancers of neurologic origin, or
3 other cancers across all contrasts (Table 3). When investigating the risk of smoking or alcohol-related
4 cancers following VB-affected vs VB-unaffected pregnancy the HR was 0.98 (95% CI: 0.79-1.22).
5 However, when following a first identifiable VB-affected vs VB-unaffected pregnancy of a woman,
6 we observed 1.3-fold increased hazard of smoking or alcohol-related cancers (HR: 1.29, 95% CI:
7 0.78-2.13) (Table 3). For contrasts of VB-affected pregnancy ending in childbirth vs pregnancy
8 ending in termination or miscarriage, the HRs for smoking or alcohol-related cancers were consistent
9 with slightly reduced risk to no association (HR: 0.84, 95% CI: 0.65-1.09 and HR: 0.77, 95% CI:
10 0.57-1.04, respectively) in analyses of all identifiable pregnancies. The latter associations could not be
11 adjusted for women's smoking status, since this information was only available for pregnancies
12 ending in a delivery.

13 As compared with having VB-unaffected pregnancy, there was no evidence of an increased risk of
14 premenopausal breast cancer (HR: 1.01, 95% CI: 0.92-1.11), cervical cancer (0.95, 0.78-1.16), ovary
15 and fallopian tube cancer (1.20, 0.84-1.71), and uterine cancer (0.85, 0.49-1.42) following VB-
16 affected pregnancy (Table 4). Similarly, we found no association with other investigated site-specific
17 cancers across comparisons with VB-unaffected pregnancy cohort and cohorts of pregnancies ending
18 in a termination or miscarriage (Table 3 in the electronic supplementary material).

19 Sensitivity analysis of pregnancies ending in delivery from 2004 onwards with additional adjustment
20 for woman's BMI in pregnancy showed results generally consistent with the findings from the main
21 analyses. The HR for smoking or alcohol-related cancers following a first identifiable VB-affected vs
22 VB-unaffected pregnancy of a woman shifted below the null value (HR: 0.50, 95% CI: 0.19-1.33);
23 however, the estimate should be interpreted with caution since it was based on few cancer events and,
24 thus, was imprecise (Table 4 in the electronic supplementary material). HRs for other cancers at
25 specific sites are available in Table 5 in the electronic supplementary material. There was no
26 increased risk of any cancer in analyses of women having their last identifiable pregnancy at the age
27 of 40 years or later (Table 6 in the electronic supplementary material).

28 **DISCUSSION**

29 **Principal findings**

30 In this registry-based cohort study, we found no evidence of an association between VB in pregnancy
31 carried to delivery and subsequent risk of cancer. When compared with having VB-unaffected
32 pregnancy, there was no increased risk of any cancer and specifically breast, cervical, ovary and
33 fallopian tube, and uterine cancer in women having VB-affected pregnancy. Analysis of a first
34 identifiable VB-affected vs VB-unaffected pregnancy of a woman showed a 1.3-fold increased hazard
35 of smoking or alcohol-related cancers; however, this association attenuated towards the null value in a

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .
Association between having a pregnancy complicated by vaginal bleeding and risk of cancer

1 sensitivity analysis. Similarly, we found no evidence of an association with any cancer or site-specific
2 cancers in women when contrasting having VB-affected pregnancy with termination or miscarriage.

3 **Comparison with other studies**

4 This study is in line with a previous Danish study reporting no association between VB in pregnancy
5 irrespective of pregnancy end and occult cancer (54). The results of this study also indirectly support
6 the findings of previous research showing that the risk of breast, ovarian and endometrial cancer was
7 not increased in women with a gestation duration of at least 33 weeks (1,2,27).

8 **Strengths and limitations**

9 Due to nearly complete administrative follow-up for every woman, selection bias at the inclusion of
10 pregnancies in the study is negligible, but potential selection bias from unidentified early miscarriages
11 cannot be ruled out. In the analyses, we controlled for multiple potential confounding factors. Data on
12 proxies of the lifestyle such as smoking and BMI were available only for pregnancies ending in
13 childbirth; moreover, data on BMI was only available for a data subset starting from 2004 and data on
14 in-vitro fertilization or subfertility status were unavailable. The 1.3-fold increased hazard of smoking
15 or alcohol-related cancers in the contrast of a first identifiable VB-affected vs VB-unaffected
16 pregnancy of a woman can potentially be explained by residual confounding by lifestyle factors such
17 as diet, physical activity, and BMI. At the same time, no lifestyle factor of women with VB in
18 pregnancy is likely to dilute the associations and, thus, is unlikely to explain the null associations in
19 analyses contrasting VB-affected pregnancy ending in delivery with having a termination or
20 miscarriage.

21 Records of VB diagnosis in pregnancy due to threatened miscarriage were not validated in the DNPR.
22 The validity of recording miscarriage diagnoses and procedures for pregnancy termination in the
23 DNPR is high (positive predictive value >90%) (37,55). We could potentially miss recurrent
24 miscarriages within 180 days of each other. However, owing to high specificity of miscarriage
25 diagnoses and few false positives, the misclassification of miscarriages is not a major concern. A
26 diagnostic work-up for threatened miscarriage includes an ultrasound for establishing pregnancy
27 viability, foetal heartbeat, and to eliminate other causes of VB such as ectopic pregnancy (8,56). The
28 prevalence of VB in this study is low (<3%) compared with estimates reported elsewhere (up to 30%)
29 (8–12). We argue that identified VB-affected pregnancies in this study had high specificity, however,
30 a sizeable proportion of VB episodes not resulting in a hospital-based encounter were missed. This
31 may cause bias only if captured episodes of VB systematically differ from all such episodes.

32 Owing to compulsory reporting of incident primary tumours, the accuracy of cancer diagnoses in the
33 DCR and its coverage is very high, with nearly 90% of tumours having a morphological verification
34 (41). Thus, misclassification of the outcome is unlikely in this study and is not expected to explain the
35 null findings. We did not censor women who would no longer be at risk of endometrial, cervical, and

It is made available under a [CC-BY-NC-ND 4.0 International license](#) .
Association between having a pregnancy complicated by vaginal bleeding and risk of cancer

- 1 uterine cancers due to hysterectomy (57,58) and the risks of these cancer outcomes may be
- 2 overestimated.

3 **CONCLUSION**

- 4 We found no strong evidence of an association between VB in pregnancy and subsequent risk of
- 5 cancer during up to 24 years of follow-up.

It is made available under a [CC-BY-NC-ND 4.0 International license](#) .
Association between having a pregnancy complicated by vaginal bleeding and risk of cancer

1 **Statements & Declarations**

2 **Funding information:** The author(s) received no specific funding for this work. Department of
3 Clinical Epidemiology, Aarhus University partaking in studies with institutional funding from
4 regulators and pharmaceutical companies, given as research grants to and administered by Aarhus
5 University. None of these projects is related to the current study.

6 **Author contributions:** ED, EHP, HTS, and VE designed the study. HTS facilitated the data
7 application. ED prepared the statistical analysis plan and conducted statistical analyses. EHP provided
8 expertise and supervision of the statistical analyses. All authors participated in the discussion of the
9 results and their interpretation. ED drafted the manuscript, organised the writing, and produced a
10 graphical presentation of the results. HTS provided clinical expertise. All authors equally participated
11 in the critical revision of the manuscript and approved its final version. HTS is the guarantor.

12 **Ethics approval and consent to participate:** No patient consent or ethical approval is required for
13 registry-based research according to Danish legislation. This study was reported to the Danish Data
14 Protection Agency through registration at Aarhus University (record number: AU-2016-051-000001,
15 sequential number 605).

16 **Consent for publication:** Not applicable.

17 **Data availability:** The pseudonymised data used in this study are stored on and accessed via the
18 secure governmental servers of Denmark Statistics (<https://www.dst.dk/>). According to Danish
19 legislation, Danish research environments may be granted access to data at an individual level. For
20 legal reasons and to protect individuals, whose data were analysed, the dataset used in this study will
21 not be made public.

22 **Competing Interests:** None declared.

1 **References:**

- 2 1. Husby A, Wohlfahrt J, Melbye M. Pregnancy duration and endometrial cancer risk: nationwide
3 cohort study. *BMJ*. 2019 Aug 14;366:l4693.
- 4 2. Husby A, Wohlfahrt J, Øyen N, Melbye M. Pregnancy duration and breast cancer risk. *Nat*
5 *Commun*. 2018 Oct 23;9(1):4255.
- 6 3. Alijotas-Reig J, Llurba E, Gris JM. Potentiating maternal immune tolerance in pregnancy: a new
7 challenging role for regulatory T cells. *Placenta*. 2014 Apr;35(4):241–8.
- 8 4. Calleja-Agius J, Schembri-Wismayer P, Calleja N, Brincat M, Spiteri D. Obstetric outcome and
9 cytokine levels in threatened miscarriage. *Gynecol Endocrinol*. 2011 Feb;27(2):121–7.
- 10 5. Alijotas-Reig J, Esteve-Valverde E, Ferrer-Oliveras R, Llurba E, Gris JM. Tumor Necrosis
11 Factor-Alpha and Pregnancy: Focus on Biologics. An Updated and Comprehensive Review.
12 *Clin Rev Allergy Immunol*. 2017 Aug;53(1):40–53.
- 13 6. Coomarasamy A, Gallos ID, Papadopoulou A, Dhillon-Smith RK, Al-Memar M, Brewin J, et al.
14 Sporadic miscarriage: evidence to provide effective care. *The Lancet*. 2021 May
15 1;397(10285):1668–74.
- 16 7. Lek SM, Ku CW, Allen JC, Malhotra R, Tan NS, Ostbye T, et al. Validation of serum
17 progesterone <35nmol/L as a predictor of miscarriage among women with threatened
18 miscarriage. *BMC Pregnancy Childbirth*. 2017 Mar 6;17(1):78.
- 19 8. Axelsen SM, Henriksen TB, Hedegaard M, Secher NJ. Characteristics of vaginal bleeding
20 during pregnancy. *European Journal of Obstetrics & Gynecology and Reproductive Biology*.
21 1995 Dec 1;63(2):131–4.
- 22 9. Smits LJM, North RA, Kenny LC, Myers J, Dekker GA, Mccowan LME. Patterns of vaginal
23 bleeding during the first 20 weeks of pregnancy and risk of pre-eclampsia in nulliparous
24 women: results from the SCOPE study. *Acta Obstetrica et Gynecologica Scandinavica*.
25 2012;91(11):1331–8.
- 26 10. Strobino B, Pantel-Silverman J. Gestational vaginal bleeding and pregnancy outcome. *American*
27 *Journal of Epidemiology*. 1989 Apr 1;129(4):806–15.
- 28 11. Wijesiriwardana A, Bhattacharya S, Shetty A, Smith N, Bhattacharya S. Obstetric Outcome in
29 Women With Threatened Miscarriage in the First Trimester. *Obstetrics & Gynecology*. 2006
30 Mar;107(3):557–62.
- 31 12. Saraswat L, Bhattacharya S, Maheshwari A, Bhattacharya S. Maternal and perinatal outcome in
32 women with threatened miscarriage in the first trimester: a systematic review. *BJOG*. 2010
33 Feb;117(3):245–57.
- 34 13. DeVilbiss EA, Naimi AI, Mumford SL, Perkins NJ, Sjaarda LA, Zolton JR, et al. Vaginal
35 bleeding and nausea in early pregnancy as predictors of clinical pregnancy loss. *American*
36 *Journal of Obstetrics and Gynecology*. 2020 Oct 1;223(4):570.e1-570.e14.
- 37 14. Sapra KJ, Joseph KS, Galea S, Bates LM, Louis GMB, Ananth CV. Signs and Symptoms of
38 Early Pregnancy Loss. *Reprod Sci*. 2017 Apr;24(4):502–13.

- 1 15. Mouri M, Hall H, Rupp TJ. Threatened Abortion [Internet]. 2017 [cited 2021 Apr 6]. Available
2 from: <http://europepmc.org/article/NBK/NBK430747>
- 3 16. Coomarasamy A, Devall AJ, Cheed V, Harb H, Middleton LJ, Gallos ID, et al. A Randomized
4 Trial of Progesterone in Women with Bleeding in Early Pregnancy. *New England Journal of*
5 *Medicine*. 2019 May 9;380(19):1815–24.
- 6 17. Ogwulu CO, Goranitis I, Devall AJ, Cheed V, Gallos ID, Middleton LJ, et al. The cost-
7 effectiveness of progesterone in preventing miscarriages in women with early pregnancy
8 bleeding: an economic evaluation based on the PRISM trial. *BJOG: An International Journal of*
9 *Obstetrics & Gynaecology*. 2020;127(6):757–67.
- 10 18. Quenby S, Gallos ID, Dhillon-Smith RK, Podesek M, Stephenson MD, Fisher J, et al.
11 Miscarriage matters: the epidemiological, physical, psychological, and economic costs of early
12 pregnancy loss. *The Lancet*. 2021 May 1;397(10285):1658–67.
- 13 19. Sipilä P, Hartikainen Sorri AL, Oja H, Wendt LV. Perinatal outcome of pregnancies
14 complicated by vaginal bleeding. *BJOG: An International Journal of Obstetrics & Gynaecology*.
15 1992;99(12):959–63.
- 16 20. Lashen H, Fear K, Sturdee DW. Obesity is associated with increased risk of first trimester and
17 recurrent miscarriage: matched case-control study. *Hum Reprod*. 2004 Jul;19(7):1644–6.
- 18 21. Ong CYT, Liao AW, Spencer K, Munim S, Nicolaides KH. First trimester maternal serum free
19 β human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of
20 pregnancy complications. *BJOG: An International Journal of Obstetrics & Gynaecology*.
21 2000;107(10):1265–70.
- 22 22. Ku CW, Allen JC, Lek SM, Chia ML, Tan NS, Tan TC. Serum progesterone distribution in
23 normal pregnancies compared to pregnancies complicated by threatened miscarriage from 5 to
24 13 weeks gestation: a prospective cohort study. *BMC Pregnancy Childbirth*. 2018 Sep
25 5;18(1):360.
- 26 23. Maconochie N, Doyle P, Prior S, Simmons R. Risk factors for first trimester miscarriage—
27 results from a UK-population-based case–control study. *BJOG: An International Journal of*
28 *Obstetrics & Gynaecology*. 2007;114(2):170–86.
- 29 24. Coomarasamy A, Harb HM, Devall AJ, Cheed V, Roberts TE, Goranitis I, et al. Progesterone to
30 prevent miscarriage in women with early pregnancy bleeding: the PRISM RCT. *Health Technol*
31 *Assess*. 2020 Jun;24(33):1–70.
- 32 25. Arck PC, Rose M, Hertwig K, Hagen E, Hildebrandt M, Klapp BF. Stress and immune
33 mediators in miscarriage. *Human Reproduction*. 2001 Jul 1;16(7):1505–11.
- 34 26. Bruckner TA, Mortensen LH, Catalano RA. Spontaneous Pregnancy Loss in Denmark
35 Following Economic Downturns. *Am J Epidemiol*. 2016 Apr 15;183(8):701–8.
- 36 27. Jordan SJ, Na R, Weiderpass E, Adami HO, Anderson KE, Brandt PA van den, et al. Pregnancy
37 outcomes and risk of endometrial cancer: A pooled analysis of individual participant data in the
38 Epidemiology of Endometrial Cancer Consortium. *International Journal of Cancer*.
39 2021;148(9):2068–78.

- 1 28. Ma H, Bernstein L, Pike MC, Ursin G. Reproductive factors and breast cancer risk according to
2 joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies.
3 Breast cancer research \square : BCR. 2006;8(4):R43.
- 4 29. Schmidt M, Pedersen L, Sorensen HT. The Danish Civil Registration System as a tool in
5 epidemiology. Eur J Epidemiol. 2014 Aug;29(8):541–9.
- 6 30. Pedersen CB. The Danish Civil Registration System. Scandinavian Journal of Public Health.
7 2011;39(7_suppl):22–5.
- 8 31. Knudsen LB, Olsen J. The Danish Medical Birth Registry. Danish medical bulletin. 1998
9 Jun;45(3):320–3.
- 10 32. Bliddal M, Broe A, Pottgard A, Olsen J, Langhoff-Roos J. The Danish Medical Birth Register.
11 Eur J Epidemiol. 2018 Jan;33(1):27–36.
- 12 33. Jensen VM, Rasmussen AW. Danish Education Registers. Scand J Public Health. 2011 Jul;39(7
13 Suppl):91–4.
- 14 34. Petersson F, Baadsgaard M, Thygesen LC. Danish registers on personal labour market
15 affiliation. Scand J Public Health. 2011 Jul 1;39(7_suppl):95–8.
- 16 35. Baadsgaard M, Quitzau J. Danish registers on personal income and transfer payments. Scand J
17 Public Health. 2011 Jul;39(7 Suppl):103–5.
- 18 36. Statistics Denmark [Internet]. 2021 [cited 2021 Jun 30]. Available from: <https://www.dst.dk/en>
- 19 37. Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sorensen HT. The Danish
20 National Patient Registry: a review of content, data quality, and research potential. Clin
21 Epidemiol. 2015;7:449–90.
- 22 38. Laugesen K, Ludvigsson JF, Schmidt M, Gissler M, Valdimarsdottir UA, Lunde A, et al. Nordic
23 Health Registry-Based Research: A Review of Health Care Systems and Key Registries. CLEP.
24 2021 Jul 19;13:533–54.
- 25 39. Mors O, Perto GP, Mortensen PB. The Danish Psychiatric Central Research Register. Scand J
26 Public Health. 2011 Jul;39(7 Suppl):54–7.
- 27 40. Pottgard A, Schmidt SAJ, Wallach-Kildemoes H, Sorensen HT, Hallas J, Schmidt M. Data
28 Resource Profile: The Danish National Prescription Registry. Int J Epidemiol. 2017 Jun
29 1;46(3):798–798f.
- 30 41. Gjerstorff ML. The Danish Cancer Registry. Scand J Public Health. 2011 Jul;39(7 Suppl):42–5.
- 31 42. Ording AG, Veres K, Farkas DK, Adelborg K, Sorensen HT. Risk of cancer in patients with
32 epistaxis and haemoptysis. Br J Cancer. 2018 Mar 20;118(6):913–9.
- 33 43. Gribsholt SB, Cronin-Fenton D, Veres K, Thomsen RW, Ording AG, Richelsen B, et al.
34 Hospital-diagnosed overweight and obesity related to cancer risk: a 40-year Danish cohort
35 study. Journal of Internal Medicine. 2020;287(4):435–47.

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .
Association between having a pregnancy complicated by vaginal bleeding and risk of cancer

- 1 44. Elser H, Skajaa N, Ehrenstein V, Fuglsang CH, Farkas DK, Sørensen HT. Cancer risk in
2 patients with migraine: A population-based cohort study in Denmark. *Headache: The Journal of*
3 *Head and Face Pain*. 2022;62(1):57–64.
- 4 45. Therneau TM, Thomas L, Elizabeth A, Cynthia C. survival: Survival Analysis [Internet]. 2021
5 [cited 2021 Apr 6]. Available from: <https://CRAN.R-project.org/package=survival>
- 6 46. RStudio Team. RStudio: Integrated Development for R [Internet]. Boston, MA: RStudio, PBC;
7 2020. Available from: <http://www.rstudio.com/>
- 8 47. R Core Team. R: A language and environment for statistical computing [Internet]. Vienna,
9 Austria; 2013. Available from: <http://www.R-project.org/>
- 10 48. Wickham H, Averick M, Bryan J, Chang W, McGowan LD, François R, et al. Welcome to the
11 Tidyverse. *Journal of Open Source Software*. 2019 Nov 21;4(43):1686.
- 12 49. Wickham H. ggplot2: Elegant Graphics for Data Analysis:Elegant Graphics for Data Analysis
13 [Internet]. Springer-Verlag New York; 2016. Available from: <https://ggplot2.tidyverse.org>
- 14 50. Gray B. cmprsk: Subdistribution Analysis of Competing Risks [Internet]. 2020 [cited 2021 Mar
15 31]. Available from: <https://CRAN.R-project.org/package=cmprsk>
- 16 51. Gerds TA. prodlim: Product-Limit Estimation for Censored Event History Analysis [Internet].
17 2019 [cited 2021 Mar 31]. Available from: <https://CRAN.R-project.org/package=prodlim>
- 18 52. Nunes MS and ES with contributions from T, Heuer C, Marshall J, Sanchez J, Thornton R,
19 Reiczigel J, et al. epiR: Tools for the Analysis of Epidemiological Data [Internet]. 2021 [cited
20 2021 Jul 29]. Available from: <https://CRAN.R-project.org/package=epiR>
- 21 53. Datatilsynet. Datatilsynet/The Danish Data Protection Agency [Internet]. Datatilsynet/The
22 Danish Data Protection Agency. [cited 2020 Sep 16]. Available from:
23 <http://www.datatilsynet.dk/english>
- 24 54. Dudukina E, Farkas DK, Horváth Puhó E, Prandoni P, Sørensen HT, Ehrenstein V. Vaginal
25 bleeding in early pregnancy and risk of occult cancer. *International Journal of Gynecology &*
26 *Obstetrics*. 2019;146(3):387–9.
- 27 55. Lohse SR, Farkas DK, Lohse N, Skouby SO, Nielsen FE, Lash TL, et al. Validation of
28 spontaneous abortion diagnoses in the Danish National Registry of Patients. *Clin Epidemiol*.
29 2010 Oct 27;2:247–50.
- 30 56. Norwitz ER, Park JS, Lockwood CJ, Barss V. Overview of the etiology and evaluation of
31 vaginal bleeding in pregnancy - UpToDate [Internet]. 2021 [cited 2021 Aug 30]. Available
32 from: [https://www.uptodate.com/contents/overview-of-the-etiology-and-evaluation-of-vaginal-](https://www.uptodate.com/contents/overview-of-the-etiology-and-evaluation-of-vaginal-bleeding-in-pregnancy)
33 [bleeding-in-pregnancy](https://www.uptodate.com/contents/overview-of-the-etiology-and-evaluation-of-vaginal-bleeding-in-pregnancy)
- 34 57. Gustafson LW, Booth BB, Kahlert J, Ørtoft G, Mejlgaard E, Clarke MA, et al. Trends in
35 hysterectomy-corrected uterine cancer mortality rates during 2002 to 2015: mortality of
36 nonendometrioid cancer on the rise? *International Journal of Cancer*. 2021;148(3):584–92.

It is made available under a [CC-BY-NC-ND 4.0 International license](#) .
Association between having a pregnancy complicated by vaginal bleeding and risk of cancer

- 1 58. Lycke KD, Kahlert J, Damgaard R, Mogensen O, Hammer A. Trends in Hysterectomy
- 2 Incidence Rates During 2000-2015 in Denmark: Shifting from Abdominal to Minimally
- 3 Invasive Surgical Procedures. CLEP. 2021 Jun 1;13:407–16.

4

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

Association between having a pregnancy complicated by vaginal bleeding and risk of cancer

Figure 1. Flow chart for the study population ascertainment

Standalone figure

Table 1. Descriptive characteristics of the VB-affected pregnancy and comparator cohorts, Denmark, 1995-2017

Characteristic	Exposed cohort		Comparator cohorts	
	VB-affected pregnancy, N = 37 082	VB-unaffected pregnancy, N = 1 363 614	Termination, N = 324 328	Miscarriage, N = 137 104
Women, N	35 514	783 314	239 638	121 353
Characteristic	n (%)^a	n (%)^a	n (%)^a	n (%)^a
Age at pregnancy end, years				
<20	565 (1.5)	20 010 (1.5)	46 215 (14.0)	4 635 (3.4)
20-24	5 030 (14.0)	163 880 (12.0)	74 390 (23.0)	17 410 (13.0)
25-29	12 265 (33.0)	464 200 (34.0)	68 090 (21.0)	37 455 (27.0)
30-34	12 380 (33.0)	476 500 (35.0)	65 425 (20.0)	39 820 (29.0)
35-39	5 720 (15.0)	202 705 (15.0)	49 490 (15.0)	26 205 (19.0)
40+	1 125 (3.0)	36 320 (2.7)	20 725 (6.4)	11 575 (8.4)
Calendar year of pregnancy end				
1995-1999	12 660 (34.0)	308 315 (23.0)	88 940 (27.0)	33 565 (24.0)
2000-2004	8 265 (22.0)	243 075 (18.0)	63 420 (20.0)	25 470 (19.0)
2005-2008	7 220 (19.0)	304 450 (22.0)	72 305 (22.0)	33 885 (25.0)
2009-2013	4 730 (13.0)	229 010 (17.0)	50 600 (16.0)	25 365 (19.0)
2013-2017	4 205 (11.0)	278 765 (20.0)	49 070 (15.0)	18 820 (14.0)
Smoking in pregnancy				
Smoker	6 990 (19.0)	209 855 (15.0)	Not available	
Non-smoker	26 205 (71.0)	1 049 620 (77.0)		
Missing	6 990 (19.0)	209 855 (15.0)		
Parity at the index date^b				
Nulliparous	0 (0.0)	0 (0.0)	205 310 (63.0)	110 460 (81.0)
Primiparous	17 105 (46.0)	629 085 (46.0)	32 775 (10.0)	10 890 (7.9)
Multiparous	19 980 (54.0)	734 530 (54.0)	86 245 (27.0)	15 750 (11.0)
Pregnancy number at the index date				
1	11 300 (30.0)	512 700 (38.0)	112 340 (35.0)	43 995 (32.0)
2	11 545 (31.0)	447 730 (33.0)	59 810 (18.0)	39 945 (29.0)
3	7 045 (19.0)	232 420 (17.0)	58 840 (18.0)	25 525 (19.0)
3+	7 190 (19.0)	170 765 (13.0)	93 340 (29.0)	27 640 (20.0)
Civil status				
Married or in partnership	22 330 (60.0)	833 375 (61.0)	102 500 (32.0)	68 615 (50.0)
Not married	10 530 (28.0)	387 465 (28.0)	165 230 (51.0)	43 105 (31.0)
Missing	4 225 (11.0)	142 775 (10.0)	56 600 (17.0)	25 385 (19.0)
Employment status				
Employed	26 970 (73.0)	1 017 935 (75.0)	194 860 (60.0)	98 695 (72.0)
Retirement or state pension	3 395 (9.2)	100 590 (7.4)	41 220 (13.0)	13 030 (9.5)
Unemployed	5 750 (16.0)	201 410 (15.0)	80 905 (25.0)	21 330 (16.0)
Missing	965 (2.6)	43 680 (3.2)	7 340 (2.3)	4 055 (3.0)
Highest achieved education				
Basic education	9 815 (26.0)	272 030 (20.0)	145 845 (45.0)	35 680 (26.0)
High school or similar	15 095 (41.0)	553 485 (41.0)	109 340 (34.0)	53 405 (39.0)
Higher education (bachelor's degree, bachelor's degree equivalent or higher)	10 605 (29.0)	473 525 (35.0)	48 940 (15.0)	41 135 (30.0)
Missing	1 570 (4.2)	64 575 (4.7)	20 205 (6.2)	6 885 (5.0)
Year-specific income, quartiles				
Q1	8 895 (24.0)	282 190 (21.0)	130 535 (40.0)	33 130 (24.0)
Q2	9 460 (26.0)	326 595 (24.0)	82 285 (25.0)	34 490 (25.0)
Q3	8 870 (24.0)	359 000 (26.0)	52 580 (16.0)	32 695 (24.0)

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

Association between having a pregnancy complicated by vaginal bleeding and risk of cancer

	Exposed cohort		Comparator cohorts	
	VB-affected pregnancy, N = 37 082	VB-unaffected pregnancy, N = 1 363 614	Termination, N = 324 328	Miscarriage, N = 137 104
Women, N	35 514	783 314	239 638	121 353
Characteristic	n (%)^a	n (%)^a	n (%)^a	n (%)^a
Q4	9 185 (25.0)	362 210 (27.0)	47 165 (15.0)	33 220 (24.0)
Missing	670 (1.8)	33 620 (2.5)	11 760 (3.6)	3 565 (2.6)
Origin				
Danish	30 930 (83.0)	1 158 025 (85.0)	273 430 (84.0)	114 750 (84.0)
Non-Danish	6 145 (17.0)	205 150 (15.0)	50 900 (16.0)	22 355 (16.0)
Missing	5 (<0.1)	445 (<0.1)	-	-
Reproductive factors history				
At least one VB diagnosis	4 870 (13.0)	66 355 (4.9)	23 940 (7.4)	17 005 (12.0)
At least one VB diagnosis within 20 gestational weeks of a pregnancy ending in a delivery	2 320 (6.3)	29 305 (2.1)	12 000 (3.7)	5 040 (3.7)
At least one termination	8 610 (23.0)	224 450 (16.0)	110 480 (34.0)	30 195 (22.0)
At least one miscarriage	8 120 (22.0)	165 775 (12.0)	38 645 (12.0)	20 940 (15.0)
Hypertensive disorders of pregnancy	1 345 (3.6)	45 100 (3.3)	10 920 (3.4)	5 525 (4.0)
Placenta praevia	95 (0.3)	3 480 (0.3)	1 040 (0.3)	475 (0.3)
Abruptio placentae	255 (0.7)	5 995 (0.4)	2 090 (0.6)	930 (0.7)
Gestational diabetes	280 (0.8)	11 020 (0.8)	2 570 (0.8)	1 550 (1.1)
Reproductive factors in a current pregnancy				
Hypertensive disorders of pregnancy	1 610 (4.3)	51 415 (3.8)	Not available	
Eclampsia superimposed on preexisting hypertension	10 (<0.1)	305 (<0.1)	Not available	
Eclampsia	20 (<0.1)	610 (<0.1)	Not available	
Preeclampsia	1 110 (3.0)	34 730 (2.5)	Not available	
Gestational hypertension	485 (1.3)	18 490 (1.4)	Not available	
Gestational proteinuria	320 (0.9)	8 345 (0.6)	Not available	
Placenta praevia	475 (1.3)	7 445 (0.5)	Not available	
Abruptio placentae	385 (1.0)	7 110 (0.5)	Not available	
Gestational diabetes	790 (2.1)	25 375 (1.9)	Not available	
Gestation age of a new-born, weeks (median, 25 th -75 th percentile)	39.0 (38.0, 40.0)	40.0 (39.0, 41.0)	Not available	
Comorbidities				
Obesity diagnosis	2 480 (6.7)	103 560 (7.6)	11 355 (3.5)	6 135 (4.5)
PCOS	405 (1.1)	12 215 (0.9)	1 150 (0.4)	1 185 (0.9)
Thyroid disorders	915 (2.5)	30 135 (2.2)	5 065 (1.6)	2 945 (2.1)
COPD	450 (1.2)	14 140 (1.0)	3 415 (1.1)	1 450 (1.1)
Chronic kidney diseases	115 (0.3)	2 755 (0.2)	770 (0.2)	305 (0.2)
Chronic liver diseases	100 (0.3)	3 330 (0.2)	950 (0.3)	385 (0.3)
Hyperlipidemia	120 (0.3)	4 085 (0.3)	1 045 (0.3)	580 (0.4)
Diabetes types 1 and 2	760 (2.0)	26 795 (2.0)	3 390 (1.0)	2 775 (2.0)
Hypertension	235 (0.6)	7 575 (0.6)	1 600 (0.5)	915 (0.7)
Any connective tissue disorder	2 930 (7.9)	71 165 (5.2)	18 715 (5.8)	8 410 (6.1)
Any psychiatric condition identified using diagnostic codes	5 145 (14.0)	140 635 (10.0)	61 995 (19.0)	17 730 (13.0)
Any psychiatric condition identified using diagnostic codes and psychotropic medication proxy	7 595 (20.0)	225 080 (17.0)	87 280 (27.0)	28 275 (21.0)
Medication use history				
NSAIDs ^c	3 135 (8.5)	87 400 (6.4)	49 615 (15.0)	21 670 (16.0)
Steroids for systemic use ^d	2 845 (7.7)	102 390 (7.5)	20 780 (6.4)	11 380 (8.3)

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .
 Association between having a pregnancy complicated by vaginal bleeding and risk of cancer

	Exposed cohort		Comparator cohorts	
	VB-affected pregnancy, N = 37 082	VB-unaffected pregnancy, N = 1 363 614	Termination, N = 324 328	Miscarriage, N = 137 104
Women, N	35 514	783 314	239 638	121 353
Characteristic	n (%)^a	n (%)^a	n (%)^a	n (%)^a

^a All counts are rounded to the nearest 5 to adhere to Denmark Statistics data confidentiality requirements; percentages $\geq 10\%$ are rounded to the nearest whole number and percentages $< 10\%$ are rounded to the first decimal place

^b Parity was included in the statistical models as nulli- or primiparous vs multiparous

^c At least one prescription 365 days before 12 gestational weeks for VB-affected and VB-unaffected pregnancies and before the index date for terminations and miscarriages

^d At least one prescription any time before 12 gestational weeks for VB-affected and VB-unaffected pregnancies and before the index date for terminations and miscarriages

COPD, chronic obstructive pulmonary disease; NSAIDs, non-steroid anti-inflammatory disease; PCOS, polycystic ovary syndrome

Table 2. Incidence rates of cancer following vaginal bleeding-affected pregnancy and comparator cohorts, 1995-2018

	Exposed cohort		Comparator cohorts					
	VB-affected pregnancy		VB-unaffected pregnancy		Termination		Miscarriage	
	No. of events ^a	Incidence Rate, 10 000 PYs (95% CI)	No. of events ^a	Incidence Rate, 10 000 PYs (95% CI)	No. of events ^a	Incidence Rate, 10 000 PYs (95% CI)	No. of events ^a	Incidence Rate, 10 000 PYs (95% CI)
Any cancer								
All identifiable pregnancies	1 320	25.36 (24.02-26.76)	40 420	24.04 (23.81-24.28)	10 300	23.89 (23.43-24.35)	4 790	26.85 (26.10-27.62)
First pregnancy	345	23.44 (21.07-26.01)	12 560	20.88 (20.51-21.24)	2 210	15.48 (14.84-16.13)	1 080	20.95 (19.73-22.23)
Hormone-related cancers								
All identifiable pregnancies	510	9.83 (9.01-10.71)	15 455	9.19 (9.05-9.34)	3 535	8.20 (7.94-8.48)	1 885	10.56 (10.09-11.05)
First pregnancy	130	8.85 (7.43-10.47)	4 580	7.61 (7.40-7.84)	670	4.70 (4.36-5.07)	415	8.02 (7.28-8.83)
Haematological cancers								
All identifiable pregnancies	50	0.99 (0.74-1.29)	1 675	1.00 (0.96-1.05)	455	1.06 (0.97-1.16)	235	1.31 (1.15-1.49)
First pregnancy	15	1.08 (0.64-1.71)	645	1.07 (0.99-1.16)	125	0.87 (0.73-1.03)	55	1.03 (0.78-1.33)
Immune-related cancers								
All identifiable pregnancies	360	6.95 (6.26-7.69)	11,660	6.94 (6.81-7.06)	2,915	6.76 (6.52-7.01)	1 175	6.60 (6.23-6.99)
First pregnancy	105	7.23 (5.95-8.70)	4 010	6.67 (6.46-6.88)	805	5.64 (5.26-6.04)	295	5.70 (5.07-6.38)
Smoking or alcohol-related cancers								
All identifiable pregnancies	65	1.29 (1.01-1.63)	1 885	1.12 (1.07-1.17)	770	1.79 (1.66-1.92)	300	1.69 (1.51-1.89)
First pregnancy	15	1.08 (0.64-1.71)	435	0.72 (0.66-0.79)	95	0.68 (0.55-0.83)	50	0.97 (0.73-1.27)
Obesity-related cancers								
All identifiable pregnancies	160	3.04 (2.59-3.54)	4 855	2.89 (2.81-2.97)	1 315	3.05 (2.89-3.22)	615	3.46 (3.20-3.74)
First pregnancy	40	2.77 (2.02-3.72)	1 410	2.34 (2.22-2.47)	220	1.56 (1.36-1.77)	135	2.58 (2.17-3.04)
Cancers of neurological origin								
All identifiable pregnancies	130	2.46 (2.06-2.92)	3 615	2.15 (2.08-2.22)	930	2.16 (2.03-2.30)	435	2.44 (2.22-2.68)

	Exposed cohort		Comparator cohorts					
	VB-affected pregnancy		VB-unaffected pregnancy		Termination		Miscarriage	
First pregnancy	30	1.96 (1.34-2.77)	1 165	1.94 (1.83-2.05)	235	1.65 (1.45-1.87)	110	2.17 (1.80-2.60)
Other cancers								
All identifiable pregnancies	30	0.58 (0.40-0.81)	930	0.55 (0.52-0.59)	250	0.58 (0.51-0.65)	115	0.63 (0.52-0.76)
First pregnancy	5	0.47 (0.21-0.93)	310	0.52 (0.46-0.58)	55	0.39 (0.29-0.50)	25	0.48 (0.32-0.70)
Selected site-specific cancers^b								
Breast cancer, premenopausal	480	9.21 (8.41-10.06)	14 655	8.72 (8.58-8.87)	3 315	7.69 (7.44-7.96)	1 770	9.93 (9.48-10.40)
Cervical cancer	100	1.96 (1.61-2.37)	3 455	2.06 (1.99-2.13)	955	2.21 (2.08-2.36)	320	1.79 (1.60-2.00)
Ovary and fallopian tube cancer	30	0.62 (0.43-0.86)	770	0.46 (0.43-0.49)	220	0.51 (0.44-0.58)	110	0.62 (0.51-0.74)
Uterine cancer	15	0.27 (0.15-0.44)	500	0.30 (0.27-0.32)	110	0.26 (0.22-0.31)	65	0.37 (0.29-0.47)

^a All counts are rounded to the nearest 5 to adhere to Statistics Denmark data confidentiality requirements

^b Computed using all identifiable pregnancies of a woman

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .
 Association between having a pregnancy complicated by vaginal bleeding and risk of cancer

Table 3. Hazard ratios for any cancer and cancer groups contrasting VB-affected pregnancy with comparator cohorts (VB-unaffected pregnancy, pregnancies ending in termination or miscarriage), Denmark, 1995-2018

Outcome	Observations	VB-affected vs VB-unaffected pregnancy ^a	VB-affected pregnancy vs termination ^b	VB-affected pregnancy vs miscarriage ^b
		HR (95% CI)		
Any cancer	All identifiable pregnancies	1.03 (0.97-1.08)	1.03 (0.97-1.09)	0.90 (0.84-0.95)
	First pregnancy	1.06 (0.95-1.18)	1.03 (0.91-1.17)	1.11 (0.98-1.25)
Hormone-related cancers	All identifiable pregnancies	1.02 (0.94-1.12)	1.01 (0.91-1.12)	0.98 (0.87-1.10)
	First pregnancy	1.06 (0.89-1.26)	1.08 (0.88-1.33)	1.08 (0.88-1.33)
Haematological cancers	All identifiable pregnancies	0.95 (0.74-1.23)	0.91 (0.69-1.20)	0.85 (0.61-1.17)
	First pregnancy	0.96 (0.58-1.57)	0.83 (0.47-1.47)	1.08 (0.60-1.91)
Immune-related cancers	All identifiable pregnancies	1.02 (0.92-1.14)	0.90 (0.80-1.02)	1.06 (0.92-1.22)
	First identifiable	1.06 (0.87-1.28)	0.97 (0.78-1.21)	1.22 (0.97-1.54)
Smoking or alcohol-related cancers	All identifiable pregnancies	0.98 (0.76-1.25)	0.84 (0.65-1.09)	0.77 (0.57-1.04)
	First identifiable	1.29 (0.78-2.13)	1.19 (0.67-2.10)	1.25 (0.70-2.24)
Obesity-related cancers	All identifiable pregnancies	1.01 (0.86-1.18)	0.99 (0.83-1.18)	0.88 (0.72-1.08)
	First identifiable	1.11 (0.81-1.51)	1.10 (0.76-1.60)	1.07 (0.74-1.54)
Cancers of neurological origin	All identifiable pregnancies	1.14 (0.96-1.36)	1.21 (0.99-1.48)	1.00 (0.79-1.27)
	First identifiable	1.00 (0.69-1.45)	1.04 (0.68-1.59)	0.89 (0.58-1.35)
Other cancers	All identifiable pregnancies	1.00 (0.70-1.44)	0.97 (0.64-1.47)	0.99 (0.61-1.61)
	First identifiable	0.90 (0.42-1.90)	1.62 (0.68-3.85)	1.15 (0.48-2.74)

^a Adjusted for age, calendar year of pregnancy end, women's parity and number of previous identifiable pregnancies, socioeconomic factors (education, employment, and year-specific income level divided into quartiles based on all included pregnancies), smoking in pregnancy, reproductive history (pre-index date vaginal bleeding, termination, or miscarriages, placental complication in previous and current deliveries), history of chronic somatic conditions, any psychiatric condition, and use of NSAIDs and steroids for systemic use before the 12 weeks of gestation for VB-affected and VB-unaffected pregnancies and before the index date for terminations and miscarriages

^b Analyses could not be adjusted for smoking in pregnancy since the data were unavailable for pregnancies ending in a termination or miscarriage

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .
 Association between having a pregnancy complicated by vaginal bleeding and risk of cancer

Table 4. Hazard ratios for breast cancer, cervical cancer, ovary and fallopian tube cancer, and uterine cancer contrasting VB-affected pregnancy with comparator cohorts, Denmark, 1995-2018

Outcome	Model	VB-affected vs VB- unaffected pregnancy ^{a,b}	VB-affected pregnancy vs termination ^{a,c}	VB-affected pregnancy vs miscarriage ^{a,c}
		HR (95% CI)		
Breast cancer, premenopausal	Crude	1.00 (0.92-1.10)	1.17 (1.06-1.29)	0.89 (0.81-0.99)
	Adjusted	1.01 (0.92-1.11)	1.07 (0.97-1.18)	1.04 (0.93-1.17)
Cervical cancer	Crude	0.95 (0.78-1.16)	0.88 (0.72-1.08)	1.09 (0.87-1.37)
	Adjusted	0.95 (0.78-1.16)	0.82 (0.66-1.02)	1.01 (0.77-1.32)
Ovary and fallopian tube cancer	Crude	1.28 (0.90-1.83)	1.21 (0.84-1.76)	0.96 (0.64-1.42)
	Adjusted	1.20 (0.84-1.71)	0.96 (0.65-1.42)	0.88 (0.56-1.38)
Uterine cancer	Crude	0.85 (0.50-1.45)	1.01 (0.58-1.76)	0.70 (0.40-1.26)
	Adjusted	0.83 (0.49-1.42)	0.96 (0.54-1.72)	0.77 (0.40-1.48)

^a Computed using all identifiable pregnancies of a woman

^b Adjusted for age, calendar year of pregnancy end, women's parity and number of previous identifiable pregnancies, socioeconomic factors (education, employment, and year-specific income level divided into quartiles based on all included pregnancies), smoking in pregnancy, reproductive history (pre-index date vaginal bleeding, termination, or miscarriages, placental complication in previous and current deliveries), history of chronic somatic conditions, any psychiatric condition, and use of NSAIDs and steroids for systemic use before the 12 weeks of gestation for VB-affected and VB-unaffected pregnancies and before the index date for terminations and miscarriages

^c Analyses could not be adjusted for smoking in pregnancy since the data were unavailable for pregnancies ending in termination or miscarriage

CI, Confidence interval; HR, Hazard ratio; VB, vaginal bleeding

